aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Go back to aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
(NASDAQ: ATYR) Delayed: 0.50 +0.01 (2.04%)
Previous Close $0.49    52 Week High
Open $0.48    52 Week Low
Day High $0.51    P/E N/A 
Day Low $0.46    EPS
Volume 1,375,046